Iradimed Corp. (IRMD) Tops Q2 EPS by 5c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
IRADIMED CORPORATION Announces Second Quarter 2021 Financial Results
July 30, 2021 7:00 AM EDTReports second quarter 2021 revenue of $9.8 million, GAAP diluted EPS of $0.12 and non-GAAP diluted EPS of $0.14Issues Q3 and full year 2021 financial guidance
WINTER SPRINGS, Fla., July 30, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATIONÂ (the Company) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (MRI) medical devices and the only known provider of a non-magnetic intravenous (IV) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures, today announced... More
